Targeting DOT1L for Degradation in MLL-rearranged Leukemia

靶向 DOT1L 降解 MLL 重排白血病

基本信息

  • 批准号:
    10411945
  • 负责人:
  • 金额:
    $ 39.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-25 至 2023-05-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract Despite marked progress in the rate of cure among patients with acute leukemia, chromosomal translocations involving the mixed lineage leukemia gene (MLL1) give rise to highly aggressive acute leukemias associated with poor clinical outcomes for pediatric and adult patients. Current treatment options are of limited effectiveness; thus, there is a pressing need for new therapies for this disease. Genetic studies have demonstrated that the histone methyltransferase DOT1L is required for the development and maintenance of MLL-rearranged (MLL-r) leukemia in model systems. Likewise, work from the previous funding cycle clearly defined a role for DOT1L inhibition in MLL-r leukemia through characterization of a potent, specific DOT1L inhibitor, EPZ-5676 (pinometostat), that has remarkably selective anti-proliferative and pro-apoptotic effects on MLL-rearranged cells. As pinometostat has progressed through Phase I clinical trials, responses and subsequent relapses imply the development of acquired resistance to the inhibitor. In this proposal, we seek to understand the biological underpinnings of DOT1L inhibitor resistance and develop a novel class of small molecule DOT1L degraders to overcome resistance. In Specific Aim 1, we seek to understand the mechanisms of resistance through detailed studies of chromatin structure and gene expression following the development of acquired resistance to DOT1L inhibitor therapy. We will also investigate the non-enzymatic role of DOT1L in MLL-r leukemia and define dependencies acquired in the resistant state. In Specific Aim 2, we will lead a chemistry and chemical biology campaign and develop an assay platform for the identification and optimization of the first small molecule degraders of endogenous DOT1L protein. In Specific Aim 3, we will utilize our cell culture and patient-derived xenograft models of MLL-r leukemia to explore the impact of DOT1L degradation on gene expression and tumor progression while driving hit-to-lead optimization of DOT1L degraders that can prompt clinical investigation. We will also test pharmacological hypotheses regarding combinatorial drug action with DOT1L degraders in predictive human models of MLL-r leukemia. We expect these aims to bring new more efficacious, less toxic therapies to children and adults diagnosed with this devastating disease.
项目总结/文摘

项目成果

期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(14)
A Bead-Based Proximity Assay for BRD4 Ligand Discovery.
AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes.
  • DOI:
    10.1016/j.ccell.2014.10.009
  • 发表时间:
    2014-12-08
  • 期刊:
  • 影响因子:
    50.3
  • 作者:
    Deshpande AJ;Deshpande A;Sinha AU;Chen L;Chang J;Cihan A;Fazio M;Chen CW;Zhu N;Koche R;Dzhekieva L;Ibáñez G;Dias S;Banka D;Krivtsov A;Luo M;Roeder RG;Bradner JE;Bernt KM;Armstrong SA
  • 通讯作者:
    Armstrong SA
Transcription control by the ENL YEATS domain in acute leukaemia.
  • DOI:
    10.1038/nature21688
  • 发表时间:
    2017-03-09
  • 期刊:
  • 影响因子:
    64.8
  • 作者:
    Erb MA;Scott TG;Li BE;Xie H;Paulk J;Seo HS;Souza A;Roberts JM;Dastjerdi S;Buckley DL;Sanjana NE;Shalem O;Nabet B;Zeid R;Offei-Addo NK;Dhe-Paganon S;Zhang F;Orkin SH;Winter GE;Bradner JE
  • 通讯作者:
    Bradner JE
Genomic dark matter sheds light on EVI1-driven leukemia.
基因组暗物质揭示了 EVI1 驱动的白血病。
  • DOI:
    10.1016/j.ccr.2014.03.031
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    50.3
  • 作者:
    Koche,RichardP;Armstrong,ScottA
  • 通讯作者:
    Armstrong,ScottA
BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.
  • DOI:
    10.1016/j.molcel.2017.06.004
  • 发表时间:
    2017-07-06
  • 期刊:
  • 影响因子:
    16
  • 作者:
    Winter GE;Mayer A;Buckley DL;Erb MA;Roderick JE;Vittori S;Reyes JM;di Iulio J;Souza A;Ott CJ;Roberts JM;Zeid R;Scott TG;Paulk J;Lachance K;Olson CM;Dastjerdi S;Bauer S;Lin CY;Gray NS;Kelliher MA;Churchman LS;Bradner JE
  • 通讯作者:
    Bradner JE
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SCOTT A ARMSTRONG其他文献

SCOTT A ARMSTRONG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SCOTT A ARMSTRONG', 18)}}的其他基金

The Center for Therapeutic Targeting of EWS-oncoproteins
EWS癌蛋白治疗靶向中心
  • 批准号:
    10671815
  • 财政年份:
    2022
  • 资助金额:
    $ 39.6万
  • 项目类别:
The Center for Therapeutic Targeting of EWS-oncoproteins
EWS癌蛋白治疗靶向中心
  • 批准号:
    10382013
  • 财政年份:
    2021
  • 资助金额:
    $ 39.6万
  • 项目类别:
Defining epigenetic mechanisms in NPM1c mutant leukemia
定义 NPM1c 突变白血病的表观遗传机制
  • 批准号:
    10184546
  • 财政年份:
    2021
  • 资助金额:
    $ 39.6万
  • 项目类别:
Defining epigenetic mechanisms in NPM1c mutant leukemia
定义 NPM1c 突变白血病的表观遗传机制
  • 批准号:
    10640846
  • 财政年份:
    2021
  • 资助金额:
    $ 39.6万
  • 项目类别:
Defining epigenetic mechanisms in NPM1c mutant leukemia
定义 NPM1c 突变白血病的表观遗传机制
  • 批准号:
    10388249
  • 财政年份:
    2021
  • 资助金额:
    $ 39.6万
  • 项目类别:
Targeting MLL/Menin in AML
AML 中的目标 MLL/Menin
  • 批准号:
    10220875
  • 财政年份:
    2017
  • 资助金额:
    $ 39.6万
  • 项目类别:
Targeting to Epigenetic Modications in ALL
针对 ALL 的表观遗传修饰
  • 批准号:
    8607317
  • 财政年份:
    2012
  • 资助金额:
    $ 39.6万
  • 项目类别:
Targeting to Epigenetic Modications in ALL
针对 ALL 的表观遗传修饰
  • 批准号:
    8725966
  • 财政年份:
    2012
  • 资助金额:
    $ 39.6万
  • 项目类别:
Targeting to Epigenetic Modications in ALL
针对 ALL 的表观遗传修饰
  • 批准号:
    8916649
  • 财政年份:
    2012
  • 资助金额:
    $ 39.6万
  • 项目类别:
Targeting to Epigenetic Modications in ALL
针对 ALL 的表观遗传修饰
  • 批准号:
    8550799
  • 财政年份:
    2012
  • 资助金额:
    $ 39.6万
  • 项目类别:

相似海外基金

Computing analysis of leukemic stem cell dynamics in acute myelocytic leukemia
急性粒细胞白血病白血病干细胞动力学的计算分析
  • 批准号:
    19K08356
  • 财政年份:
    2019
  • 资助金额:
    $ 39.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Generation of immunotoxins with super-targeting mAb in the acute myelocytic leukemia
在急性髓细胞白血病中使用超靶向单克隆抗体产生免疫毒素
  • 批准号:
    23501309
  • 财政年份:
    2011
  • 资助金额:
    $ 39.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
  • 批准号:
    3556971
  • 财政年份:
    1980
  • 资助金额:
    $ 39.6万
  • 项目类别:
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
  • 批准号:
    3556968
  • 财政年份:
    1980
  • 资助金额:
    $ 39.6万
  • 项目类别:
ERADICATION OF ACUTE MYELOCYTIC LEUKEMIA CELLS BY MAB THERAPY
通过 MAB 疗法根除急性粒细胞白血病细胞
  • 批准号:
    3889304
  • 财政年份:
  • 资助金额:
    $ 39.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了